Cargando…
Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma
BACKGROUND: Although there have been indirect comparisons of the relative efficacy of mepolizumab (anti-IL-5) and benralizumab (anti-IL-5Rα) in severe asthma patients, long-term direct head-to-head comparisons are lacking. Here, we (i) examined the effect of mepolizumab, benralizumab, and omalizumab...
Autores principales: | AlShareef, Saad, McDonald, Christine F, Lee, Joy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857973/ https://www.ncbi.nlm.nih.gov/pubmed/35210787 http://dx.doi.org/10.2147/JAA.S348137 |
Ejemplares similares
-
Severe asthma: anti-IgE or anti-IL-5?
por: Papathanassiou, Evgenia, et al.
Publicado: (2016) -
Anti- IgE treatment in asthma: is atopy essential?
por: Gulec, Mustafa, et al.
Publicado: (2015) -
A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma
por: D’Amato, Gennaro, et al.
Publicado: (2007) -
Cumulative IgE-levels specific for respiratory allergens as biomarker to predict efficacy of anti-IgE-based treatment of severe asthma
por: Naumova, Veronika, et al.
Publicado: (2022) -
Against all odds: anti-IgE for intrinsic asthma?
por: Lommatzsch, Marek, et al.
Publicado: (2014)